Skip to main content
SpringerLink
Log in

Benign and Malignant Diseases of the Prostate

  • Chapter
  • First Online:
Principles and Practice of Geriatric Surgery

Abstract

Benign prostatic hyperplasia (BPH) and prostate cancer are two common neoplastic processes that occur in elderly men. Both of these conditions are rare before the age of 50, but by age 80 more than 80% of men have pathologic evidence of benign hyperplasia and more than 50% have at least microscopic foci of prostate cancer [1, 2]. While BPH associated urinary symptoms will impact quality of life in most elderly men, the likelihood of prostate cancer resulting in significant morbidity remains low [3, 4]. This chapter reviews the incidence of these two diseases, the appropriate evaluation of elderly men and surgical options available to the geriatric patient as well as expected outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Berry SJ, Coffey DS, Walsh PC, Ewing LL (1984) The development of human benign prostatic hyperplasia with age. J Urol 132:474

    PubMed  CAS  Google Scholar 

  2. Gaynor EP (1938) Zur frage des prostatakrebes. Virchows Arch Pathol Anat 301:602–652

    Article  Google Scholar 

  3. Jacobson ST, Jacobson DJ, Girman CJ (1999) et al; Treatment for benign protstatic hyperplasia among community dwelling men: The Olmsted county study of urinary symptoms and health status. J Urol 162:1301–1306

    Article  PubMed  Google Scholar 

  4. Ketchandji M, Kuo YF, Shahinian VB et al (2009) Cause of death in older men after the diagnosis of prostate cancer. J Am Geriatr Soc 57(5):934–935. doi:10.1111/j.1532-5415.2008.02091

    Article  Google Scholar 

  5. Caine M, Schuger L (1987) The “Capsule” in benign prostatic hypertrophy. US Department of Health and Human Services, Bethesda, p 221, NIH Publ No. 87-2881

    Google Scholar 

  6. Taylor JA 3rd, Kuchel GA (2006) Detrusor underactivity: Clinical features and pathogenesis of an underdiagnosed geriatric condition. J Am Geriatr Soc 54(12):1920–1932

    Article  PubMed  Google Scholar 

  7. Roberts RO, Bergstralh EJ, Cunningham JM et al (2004) Androgen receptor gene polymorphisms and increased risk of urologic measures of benign prostatic hyperplasia. Am J Epidemiol 159:269–276

    Article  PubMed  Google Scholar 

  8. Roberts RO, Jacobson DJ, Rhodes T et al (2004) Serum sex hormones and measures of benign prostatic hyperplasia. Prostate 61:124–131

    Article  PubMed  CAS  Google Scholar 

  9. Arrighi HM, Guess HA, Metter EJ et al (1990) Symptoms and signs of prostatism as risk factors for prostatectomy. Prostate 16:253

    Article  PubMed  CAS  Google Scholar 

  10. Elbadawi A, Yalla SV, Resnick NM (1993) Structural basis of geriatric voiding dysfunction. I. Methods of a prospective ultrastructural/urodynamic study and an overview of the findings. J Urol 150:1650–1656

    PubMed  CAS  Google Scholar 

  11. Malone-Lee J, Wahedna I (1993) Characterisation of detrusor contractile function in relation to old age. Br J Urol 72:873–880

    Article  PubMed  CAS  Google Scholar 

  12. Van Mastrigt R (1992) Age dependence of urinary bladder contractility. Neurourol Urodynam 11:315

    Google Scholar 

  13. Resnick NM, Yalla SV (1987) Detrusor hyperactivity with impaired contractility: An unrecognized but common cause of incontinence in elderly patients. JAMA 257:3076–3081

    Article  PubMed  CAS  Google Scholar 

  14. Resnick NM, Yalla SV, Laurino E (1989) The pathophysiology of urinary incontinence among institutionalized elderly persons. N Engl J Med 320:1–7

    Article  PubMed  CAS  Google Scholar 

  15. Chaikin DC, Blaivas JG (2001) Voiding dysfunction: definitions. Curr Opin Urol 11:395–398

    Article  PubMed  CAS  Google Scholar 

  16. Weiss JP, Blaivas JG (2000) Nocturia. J Urol 163:5–12

    Article  PubMed  CAS  Google Scholar 

  17. Su L, Guess HA, Girman CJ et al (1996) Adverse effects of medications on urinary symptoms and flow rate: a community-based study. J Clin Epidemiol 49:483–487

    Article  PubMed  CAS  Google Scholar 

  18. McConnell JD, Barry MJ, Bruskewitz RC et al (1994) Benign prostatic hyperplasia: diagnosis and treatment. clinical practice guideline number 8. Agency for Health Care Policy & Research, Public Health Service, US Department of Health and Human Services, Rockville, MD, AHCPR Publ No. 94-0582

    Google Scholar 

  19. Mebust WK, Holtgrewe HL, Cockette ATK, Peters PC, Committee W (1989) Transurethral prostatectomy: immediate and postoperative complications: a cooperative study of 13 participating institutions evaluating 3885 patients. J Urol 141:243–247

    PubMed  CAS  Google Scholar 

  20. Melchoir J, Valk WL, Foret JD, Mebust MK (1974) Transurethral prostatectomy in the azotemic patient. J Urol 112:643–646

    Google Scholar 

  21. Wasson JH, Reda DJ, Bruskewitz RC et al (1995) A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. N Engl J Med 332:75–79

    Article  PubMed  CAS  Google Scholar 

  22. Gacci M, Bartoletti R, Figlioli S et al (2003) Urinary symptoms, quality of life and sexual function in patients with benign prostatic hypertrophy before and after prostatectomy: A prospective study. BJU Int 91:196–200

    Article  PubMed  CAS  Google Scholar 

  23. Barry MJ, Fowler FJ Jr, O’Leary MP et al (1992) The American Urological Association’s symptom index for benign prostatic hyperplasia. J Urol 148:1549–1557, Copyright (c) 1992, Lea & Febiger

    PubMed  CAS  Google Scholar 

  24. Stanford JL, Stephenson RA, Coyle LM et al (1999) Prostate cancer trends 1973–1995, SEER program. National Cancer Institute, Bethesda, NIH Pub No. 99-4543

    Google Scholar 

  25. Jemal A, Siegel R, Ward E et al (2008) Cancer statistics 2008. CA Cancer J Clin 58:71–96

    Article  PubMed  Google Scholar 

  26. Edwards CN, Steinthorsson E, Nicholson D (1953) An autopsy study of latent prostatic cancer. Cancer 32:498–506

    Google Scholar 

  27. Halpert B, Sheehan EE, Schmalhorst WR, Scott R (1963) Carcinoma of the prostate: a survey of 5000 autopsies. Cancer 16:737–742

    Article  PubMed  CAS  Google Scholar 

  28. Shimizu H, Ross RK, Bernstein L et al (1991) Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. Br J Cancer 63:963–966

    Article  PubMed  CAS  Google Scholar 

  29. Yatani R, Chigusa I, Akazaki K et al (1982) Geographic pathology of latent prostatic carcinoma. Int J Cancer 29:611–616

    Article  PubMed  CAS  Google Scholar 

  30. Smith JR, Freije D, Carpten JD et al (1996) Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 274:1371–1374

    Article  PubMed  CAS  Google Scholar 

  31. Steinberg GS, Carter BS, Beaty TH et al (1990) Family history and the risk of prostate cancer. Prostate 17:337–340

    Article  PubMed  CAS  Google Scholar 

  32. Draisma G, Boer R, Otto SJ et al (2003) Lead times and over detection due to prostate specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 95:868–878

    Article  PubMed  Google Scholar 

  33. U.S. Preventive Services Task Force (2008) Screening for prostate cancer: U.S. Preventive Services Task Force Recommendation statement. Ann Internal Med 149:185–191

    Google Scholar 

  34. Byar DP, Mostofi FK (1972) Veterans Administration Cooperative Urologic Research Groups: carcinoma of the prostate: prognostic evaluation of certain pathologic features in 208 radical prostatectomies. Cancer 30:5–13

    Article  PubMed  CAS  Google Scholar 

  35. McNeal JE (1992) Cancer volume and site of origin of adenocarcinoma of the prostate: relationship to local and distant spread. Hum Pathol 23:258–266

    Article  PubMed  CAS  Google Scholar 

  36. Gleason DF, Mellinger GT (1974) Veterans Administration Cooperative Urological Research Group: prediction of prognosis for prostatic adenocarcinoma by combined histologic grading and clinical staging. J Urol 111:58–64

    PubMed  CAS  Google Scholar 

  37. Albertsen PC, Hanley JA, Fine J (2005) 20 year outcomes following conservative management of clinically localized prostate cancer. JAMA 293:2095–2101

    Article  PubMed  CAS  Google Scholar 

  38. Albertsen PC, Hanley JA, Barrows GH et al (2005) Prostate cancer and the Will Rogers Phenomenon. JNCI 97(17):1248–1253

    Article  PubMed  Google Scholar 

  39. Gilliland F, Becker TM, Smith A et al (1994) Trends in prostate cancer incidence and mortality in New Mexico are consistent with an increase in effective screening. Cancer Epidemiol Biol Prev 3:105–111

    CAS  Google Scholar 

  40. Ellis WJ, Chetner MP, Preston SD, Brawer MK (1994) Diagnosis of prostatic carcinoma: the yield of serum prostate specific antigen, digital rectal examination and transrectal ultrasonography. J Urol 52:1520–1525

    Google Scholar 

  41. Oesterling JE, Jacobsen SJ, Chute CG et al (1993) Serum prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. JAMA 270:860–864

    Article  PubMed  CAS  Google Scholar 

  42. Benson MC, Whang IS, Olsson CA et al (1992) Use of prostate specific antigen density to enhance predictive value of intermediate levels of serum prostate specific antigen. J Urol 147:817–821

    PubMed  CAS  Google Scholar 

  43. Carter HB, Pearson JD, Metter JE et al (1992) Longitudinal evaluation of prostate specific antigen levels in men with and without prostate disease. JAMA 267:2215–2220

    Article  PubMed  CAS  Google Scholar 

  44. Catalona WJ, Simth DS, Wolfert RL et al (1995) Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 274:1214–1220

    Article  PubMed  CAS  Google Scholar 

  45. Albertsen PC, Hanley JA, Harlan JC et al (2000) The positive yield of imaging studies in the evaluation of men with newly diagnosed prostate cancer: a population-based analysis. J Urol 163:1138–1143

    Article  PubMed  CAS  Google Scholar 

  46. Catalona WJ, Smith DS, Ratliff TL, Basler JW (1993) Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based testing. JAMA 270:948–954

    Article  PubMed  CAS  Google Scholar 

  47. Johansson JE, Homberg L, Johansson S et al (1997) Fifteen year survival in prostate cancer: a prospective, population-based study in Sweden. JAMA 277:467–471

    Article  PubMed  CAS  Google Scholar 

  48. Chodak GW, Thisted RA, Gerber GS et al (1994) Results of ­conservative management of clinically localized prostate cancer. N Engl J Med 330:242–248

    Article  PubMed  CAS  Google Scholar 

  49. Albertsen PC, Fryback DG, Storer BE et al (1995) Long term survival among men with conservatively treated localized prostate cancer. JAMA 274:626–631

    Article  PubMed  CAS  Google Scholar 

  50. Albertsen PC, Hanley JA, Gleason DF, Barry MJ (1998) Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 280:975–980

    Article  PubMed  CAS  Google Scholar 

  51. Albertsen PC, Fryback DG, Storer BE et al (1996) The impact of co-morbidity on life expectancy among men with localized prostate cancer. J Urol 156:127–132

    Article  PubMed  CAS  Google Scholar 

  52. Lu-Yao GL, Albertsen PC, Warren J, Yao SL (1999) Effect of age and surgical approach on complications and short-term mortality after radical prostatectomy: a population-based study. Urology 54:301–307

    Article  PubMed  CAS  Google Scholar 

  53. Fowler FJ, Barry MJ, Lu-Yao G et al (1993) Patient-reported complications and follow-up treatment after radical prostatectomy. J Urol 149:622–629

    Google Scholar 

  54. Eastham JA, Kattan MW, Rogers E et al (1996) Risk factors for urinary incontinence after radical retropubic prostatectomy. J Urol 156:1707–1713

    Article  PubMed  CAS  Google Scholar 

  55. Stanford JL, Feng Z, Hamilton AS et al (2000) Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: The Prostate Cancer Outcomes Study. JAMA 283:354–360

    Article  PubMed  CAS  Google Scholar 

  56. Quinlan DM, Epstein JI, Carter BS, Walsh PC (1991) Sexual function following radical prostatectomy: influence of reservation of neurovascular bundles. J Urol 145:998–1002

    PubMed  CAS  Google Scholar 

  57. Murphy GP, Mettlin C, Menck H et al (1994) National patterns of prostate cancer treatment by radical prostatectomy: results of a survey by the American College of Surgeons Committee on Cancer. J Urol 152:1817–1819

    PubMed  CAS  Google Scholar 

  58. Bill-Axelson A, Holmber L, Filen F et al (2008) Radical prostatectomy versus watchful waiting in localized prostate cancer: The Scandinavian prostate cancer Group-4 randomized trial. JNCI 100:1144–1154

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Urology, Department of Surgery, University of Connecticut Health Center, 263 Farmington Avenue, Farmingto, CT, 06030, USA

    John A. Taylor III

Authors
  1. John A. Taylor III
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter C. Albertsen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John A. Taylor III .

Editor information

Editors and Affiliations

  1. School of Medicine, Department of Surgery, Yale University, New Haven, 06520, Connecticut, USA

    Ronnie Ann Rosenthal

  2. Downstate Medical Center, State University of New York, Clarkson Ave. 450, Brooklyn, 11203, New York, USA

    Michael E. Zenilman

  3. , Chairman, Department of Surgery, Sinai Hospital, 2401 West Belvedere Avenue, Baltimore, 21215, Maryland, USA

    Mark R. Katlic

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Taylor, J.A., Albertsen, P.C. (2011). Benign and Malignant Diseases of the Prostate. In: Rosenthal, R., Zenilman, M., Katlic, M. (eds) Principles and Practice of Geriatric Surgery. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-6999-6_81

Download citation

  • DOI: https://doi.org/10.1007/978-1-4419-6999-6_81

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4419-6998-9

  • Online ISBN: 978-1-4419-6999-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation